These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 24848754)

  • 21. Iron-based phosphate binders--a new element in management of hyperphosphatemia.
    Pai AB; Jang SM; Wegrzyn N
    Expert Opin Drug Metab Toxicol; 2016; 12(1):115-27. PubMed ID: 26572591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease.
    Yang X; Bai Q; Li Y; Liu H; Guo H; Zhang X
    JPEN J Parenter Enteral Nutr; 2018 May; 42(4):766-777. PubMed ID: 28777915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide.
    Cernaro V; Santoro D; Lacquaniti A; Costantino G; Visconti L; Buemi A; Buemi M
    Int J Nephrol Renovasc Dis; 2016; 9():11-9. PubMed ID: 26893577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel iron-containing phosphate binders for treatment of hyperphosphatemia.
    Schmid H; Lederer SR
    Expert Opin Pharmacother; 2015; 16(14):2179-91. PubMed ID: 26293683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphate binders in chronic kidney disease: a systematic review of recent data.
    Floege J
    J Nephrol; 2016 Jun; 29(3):329-340. PubMed ID: 26800972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients.
    Yoshida T; Morimoto K; Kaburagi N; Fujino T; Takemitsu TY; Yamashita N; Oya M
    Int Urol Nephrol; 2022 Apr; 54(4):861-872. PubMed ID: 34264473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease.
    Geisser P; Philipp E
    Clin Nephrol; 2010 Jul; 74(1):4-11. PubMed ID: 20557860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Rising Risk of Chronic Kidney Disease (CKD) and How it is Dealt with: A Review of Current and Potential Phosphate Binders (PB).
    Gosik R; Danel K
    Mini Rev Med Chem; 2021; 21(19):3052-3061. PubMed ID: 34137362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
    Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
    Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
    Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
    Koiwa F; Terao A
    Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited.
    Nakanishi T; Hasuike Y; Nanami M; Yahiro M; Kuragano T
    Nephrol Dial Transplant; 2016 Oct; 31(10):1588-94. PubMed ID: 26142396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
    Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
    Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and potential treatment options for hyperphosphatemia.
    Carfagna F; Del Vecchio L; Pontoriero G; Locatelli F
    Expert Opin Drug Saf; 2018 Jun; 17(6):597-607. PubMed ID: 29783873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
    Ketteler M; Sprague SM; Covic AC; Rastogi A; Spinowitz B; Rakov V; Walpen S; Floege J
    Nephrol Dial Transplant; 2019 Jul; 34(7):1163-1170. PubMed ID: 29846719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Phosphate Binder Use among Dialysis-Dependent Patients with CKD.
    Berner T; Ferro C; Dieguez G; Metz S; Moore J; Szabo E; Kovesdy CP
    Nephron; 2023; 147(10):583-590. PubMed ID: 36996774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.
    Floege J; Covic AC; Ketteler M; Rastogi A; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
    Kidney Int; 2014 Sep; 86(3):638-47. PubMed ID: 24646861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Iron-based Phosphate Binders for ESRD Patients].
    Cozzolino M; Mangano M; Magagnoli L; Di Lullo L; Galassi A; Brancaccio D; Bellasi A
    G Ital Nefrol; 2016; 33(4):. PubMed ID: 27545638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.